Fero Industries, Inc. is a publicly traded company focused on diabetes prevention and treatments (OTCBB: FROI). The Company holds the intellectual property and other exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, a treatment for Type II diabetes.
Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.
Sucanon® has undergone clinical trials in China and Brazil. Sucanon® is approved and is sold as an Over-The-Counter ("OTC") treatment for Type II diabetes in Mexico and as an prescription pharmaceutical in Peru. An application for United States FDA approval of Sucanon® has not been made.
Type II diabetics in the United States can may buy Sucanon® for their own use and have it delivered to them from Mexico under the U.S. FDA’s “personal importation�guidelines. A similar program exists for Type II diabetics in Canada who wish to buy Sucanon® for their own use. The Company will consider applying for FDA approval in the near future.
Download the latest
Fero Industries Corporate Profile
